NCT02251041View on ClinicalTrials.gov

Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)

PHASE2CompletedINTERVENTIONAL

Enrollment

143

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

February 28, 2019

Study Completion Date

August 31, 2019

Conditions

Reperfusion Injury

Interventions

DRUG

Antithrombin-III

DRUG

Infliximab

DRUG

Apotransferrin

DRUG

Human recombinant erythropoietin

DRUG

C1-Inhibitor

DRUG

Glutathione

DRUG

Alfa-tocopherol

DRUG

Melatonin

DRUG

Epoprostenol

DRUG

Sodium chloride solution

Trial Locations (1)

3000

University Hospitals Leuven, Leuven

All Listed Sponsors

lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT02251041 - Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL) | Biotech Hunter | Biotech Hunter